1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exagen Inc.
  6. News
  7. Summary
    XGN   US30068X1037

EXAGEN INC.

(XGN)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
5.800 USD   -4.29%
06/21EXAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/09Exagen Inc. Expands Coverage with MediNcrease
GL
06/09Exagen Inc. Expands Coverage with MediNcrease
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus

05/16/2022 | 04:05pm EDT

Exagen Inc. announced that AVISE® CTD and AVISE® Lupus are a contracted covered service with Alivio Health, providing enhanced care to their 150,000 members. The agreement also makes AVISE® diagnostic testing available as an in-network benefit.


© S&P Capital IQ 2022
All news about EXAGEN INC.
06/21EXAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/09Exagen Inc. Expands Coverage with MediNcrease
GL
06/09Exagen Inc. Expands Coverage with MediNcrease
AQ
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
GL
05/26Exagen Inc. to Participate in the William Blair 42nd Annual Growth Stock Conference
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
GL
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
AQ
05/16Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di..
CI
05/13KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating
MT
05/11EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
More news
Analyst Recommendations on EXAGEN INC.
More recommendations
Financials (USD)
Sales 2022 53,4 M - -
Net income 2022 -35,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,79x
Yield 2022 -
Capitalization 94,3 M 94,3 M -
Capi. / Sales 2022 1,77x
Capi. / Sales 2023 1,43x
Nbr of Employees 221
Free-Float 58,9%
Chart EXAGEN INC.
Duration : Period :
Exagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EXAGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 5,80 $
Average target price 16,40 $
Spread / Average Target 183%
EPS Revisions
Managers and Directors
Fortunato Ron Rocca President, Chief Executive Officer & Director
Kamal Adawi Chief Financial Officer & Secretary
Brian P. Birk Chairman
Debra Jeske Zack Chief Medical Officer
Anja Kammesheidt Chief Scientific Officer
Sector and Competitors